{"nctId":"NCT00259012","briefTitle":"Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD","startDateStruct":{"date":"2005-11"},"conditions":["Gastroesophageal Reflux"],"count":67,"armGroups":[{"label":"Low dose","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: pantoprazole sodium enteric-coated spheroid suspension"]},{"label":"High dose","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: pantoprazole sodium enteric-coated spheroid suspension"]}],"interventions":[{"name":"pantoprazole sodium enteric-coated spheroid suspension","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Greater than 44 weeks beyond neonatal period but less than 12 months\n* Presumptive diagnosis of GERD\n* Weight greater than 2.5 kg but less than 15 kg\n\nExclusion Criteria:\n\n* History of gastrointestinal (GI) disorders, ie, unrepaired tracheal esophageal fistula, GI malabsorption\n* Clinically significant medical or surgical abnormalities","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Month","maximumAge":"11 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Peak Concentration (Cmax)","description":"Pharmacokinetic (PK) parameters, including peak plasma concentration, were determined following a single oral dose of pantoprazole","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"567","spread":"534"},{"groupId":"OG001","value":"1527","spread":"1298"}]}]}]},{"type":"PRIMARY","title":"Time to Peak Concentration (Tmax) Profile","description":"Pharmacokinetic (PK) parameters, including time to peak plasma concentration, were determined following a single oral dose of pantoprazole.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":null},{"groupId":"OG001","value":"1.02","spread":null}]}]}]},{"type":"PRIMARY","title":"Disposition Half-life","description":"Pharmacokinetic (PK) parameters, including the terminal-phase disposition half-life, were determined following a single oral dose of pantoprazole. Half-life is the time required for half the quantity of absorbed drug to be metabolized or eliminated by normal biological processes.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.78","spread":"1.30"},{"groupId":"OG001","value":"1.42","spread":"0.78"}]}]}]},{"type":"PRIMARY","title":"Area Under the Concentration-time Curve (AUC)","description":"Pharmacokinetic (PK) parameters, including AUC, were determined following a single oral dose of pantoprazole. AUC is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1046","spread":"1043"},{"groupId":"OG001","value":"3602","spread":"3269"}]}]}]},{"type":"PRIMARY","title":"Apparent Oral Clearance (CL/F)","description":"Pharmacokinetic (PK) parameters, including apparent oral clearance, were determined following a single oral dose of pantoprazole. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.54","spread":"2.35"},{"groupId":"OG001","value":"0.87","spread":"1.36"}]}]}]},{"type":"PRIMARY","title":"Pantoprazole Plasma Concentration After Multiple-Dose Oral Administration","description":"Plasma concentration of pantoprazole after multiple doses was measured to see if there was any accumulation of the drug.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"289","spread":"354"},{"groupId":"OG001","value":"668","spread":"825"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":"102"},{"groupId":"OG001","value":"353","spread":"509"}]}]}]},{"type":"PRIMARY","title":"Intragastric pH","description":"Intragastric pH is a method for evaluating gastric acidity scaled 0-9. A lower pH means more acidity. A longer duration of esophageal mucosa exposure to a gastric refluxate with a pH \\<4.0 correlates with more severe mucosal injury in patients with gastroesophageal reflux disease (GERD).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"1.4"},{"groupId":"OG001","value":"3.0","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"1.3"},{"groupId":"OG001","value":"4.2","spread":"1.5"}]}]}]},{"type":"PRIMARY","title":"Median Intragastric pH","description":"Intragastric pH is a method for evaluating gastric acidity scaled 0-9. A lower pH means more acidity. A longer duration of esophageal mucosa exposure to a gastric refluxate with a pH \\<4.0 correlates with more severe mucosal injury in patients with gastroesophageal reflux disease (GERD).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"1.7"},{"groupId":"OG001","value":"2.8","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"1.7"},{"groupId":"OG001","value":"4.2","spread":"1.9"}]}]}]},{"type":"PRIMARY","title":"Percentage of Time Intragastric pH Was >4","description":"Intragastric pH is a method for evaluating gastric acidity. A lower pH means more acidity. A longer duration of esophageal mucosa exposure to a gastric refluxate with a pH \\<4.0 correlates with more severe mucosal injury in patients with gastroesophageal reflux disease (GERD).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.5","spread":"28.6"},{"groupId":"OG001","value":"32.2","spread":"24.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.5","spread":"28.3"},{"groupId":"OG001","value":"56.6","spread":"31.1"}]}]}]},{"type":"PRIMARY","title":"Mean Intraesophageal pH","description":"Intraesophagel pH is a method for evaluating acidity of gastric refluxate scaled 0-9. A lower pH means more acidity. A longer duration of esophageal mucosa exposure to a gastric refluxate with a pH \\<4.0 correlates with more severe mucosal injury in patients with gastroesophageal reflux disease (GERD).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":"0.7"},{"groupId":"OG001","value":"5.2","spread":"0.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"0.8"},{"groupId":"OG001","value":"4.9","spread":"0.3"}]}]}]},{"type":"PRIMARY","title":"Median Intraesophageal pH","description":"Intraesophagel pH is a method for evaluating acidity of gastric refluxate scaled 0-9. A lower pH means more acidity. A longer duration of esophageal mucosa exposure to a gastric refluxate with a pH \\<4.0 correlates with more severe mucosal injury in patients with gastroesophageal reflux disease (GERD).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":"0.7"},{"groupId":"OG001","value":"5.3","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"0.8"},{"groupId":"OG001","value":"4.9","spread":"0.4"}]}]}]},{"type":"PRIMARY","title":"Percentage of Time That Intraesophageal pH Was <4","description":"Intraesophagel pH is a method for evaluating acidity of gastric refluxate. A lower pH means more acidity. A longer duration of esophageal mucosa exposure to a gastric refluxate with a pH \\<4.0 correlates with more severe mucosal injury in patients with gastroesophageal reflux disease (GERD).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"3.9"},{"groupId":"OG001","value":"8.0","spread":"5.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"5.6"},{"groupId":"OG001","value":"9.4","spread":"5.8"}]}]}]},{"type":"PRIMARY","title":"Normalized Area of Gastric Hydrogen Ion Activity Over Time","description":"Normalized Area of Gastric Hydrogen Ion Activity Over Time is a measure of the area under the curve of the gastric hydrogen ion activity over time, which is normalized for a 24-hour period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"259.7","spread":"442.7"},{"groupId":"OG001","value":"921.0","spread":"1290.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102.3","spread":"118.6"},{"groupId":"OG001","value":"303.6","spread":"524.9"}]}]}]},{"type":"PRIMARY","title":"Normalized Area of Esophageal Hydrogen Ion Activity Over Time","description":"Normalized Area of Esophageal Hydrogen Ion Activity Over Time is a measure of the area under the curve of the esophageal hydrogen ion activity over time, which is normalized for a 24-hour period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"1.6"},{"groupId":"OG001","value":"3.5","spread":"2.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"2.4"},{"groupId":"OG001","value":"1.5","spread":"0.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3},"commonTop":["Fever","Diarrhea","Contact dermatitis","Rhinitis","Infection"]}}}